Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ)

Group 1 - Truist Securities initiated coverage of Janux Therapeutics with a Buy recommendation [2] - A target price of $100 was set for Janux Therapeutics [2] - The recommendation is based on a catalyst-rich period expected for the company in the second half of the year [2]